NAMS
NewAmsterdam Pharma Company N.V.
$35.07
$0.00(0.00%)
52
Overall
--
Value
90
Tech
15
Quality
Market Cap
$3.90B
Volume
425.94K
52W Range
$14.06 - $42.00
Target Price
$49.92
Company Overview
| Mkt Cap | $3.90B | Price | $35.07 |
| Volume | 425.94K | Change | +0.00% |
| P/E Ratio | -16.1 | Open | $33.90 |
| Revenue | $45.6M | Prev Close | $35.07 |
| Net Income | $-241.6M | 52W Range | $14.06 - $42.00 |
| Div Yield | N/A | Target | $49.92 |
| Overall | 52 | Value | -- |
| Quality | 15 | Technical | 90 |
No chart data available
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
NewAmsterdam Pharma Company (NAMS) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•8 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $35.07 | 0% | 425.94K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW